MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

35.57 -6.96

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

34.58

Max

38.22

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	11.593 87.826
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+15.74% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	429M 2.1B
Eelmine avamishind	42.53
Eelmine sulgemishind	35.57

Uudiste sentiment

By Acuity

35%

65%

128 / 370 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. jaan 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. jaan 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. jaan 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. jaan 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. jaan 2026, 20:54 UTC

Tulu

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. jaan 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. jaan 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. jaan 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. jaan 2026, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. jaan 2026, 19:22 UTC

Omandamised, ülevõtmised, äriostud

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. jaan 2026, 18:21 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. jaan 2026, 18:20 UTC

Omandamised, ülevõtmised, äriostud

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. jaan 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. jaan 2026, 18:16 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. jaan 2026, 18:01 UTC

Omandamised, ülevõtmised, äriostud

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. jaan 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

15.74% tõus

12 kuu keskmine prognoos

Keskmine 43.83 USD 15.74%

Kõrge 55 USD

Madal 32 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

128 / 370 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.